South African Explores Omicron Vax, Biden Vs. Omicron, UK’s Big Booster Plan, World Stats…US Passes 800,000 Deaths

- Advertisement -

South African scientists explore vaccines’ effectiveness against Omicron

Crucial work will study how well current jabs work and whether they need to be updated to tackle new variant

Covid-19 vaccine being prepared
A Covid-19 vaccine being prepared. The Omicron variant carries dozens of mutations that are expected to change how the virus behaves. Photograph: Maureen McLean/Rex/Shutterstock

Scientists in South Africa have begun crucial work to assess how well Covid vaccines hold up against the Omicron variant that has been detected in more than a dozen countries since it was formally reported last week.

The variant carries dozens of mutations that are expected to change how the virus behaves, including its ability to cause infection and how well it can hide from immune defences primed by vaccines or previous infection with an older variant.

Covid-19 lateral flow testing kits being given out to shoppers at the Amersham weekly market in Buckinghamshire.
UK science advisers brace for hundreds of confirmed Omicron Covid cases
Read more

Antibodies protect against viruses by gumming them up and preventing them from infecting human cells. To do so, they must recognise particular parts of the virus. Most Covid antibodies latch on to one of three sites on the virus, but all are mutated in Omicron, meaning antibodies produced by vaccines or past infection may be significantly less effective.

Prof Penny Moore at the University of the Witwatersrand and the National Institute for Communicable Disease in South Africa said “pseudoviruses” – harmless, non-replicating viruses used to model coronavirus variants – will be engineered to carry Omicron’s mutations. These will then be exposed to antibody-carrying blood plasma from vaccinated people and those who have recovered from Covid infection to see if they neutralise the virus.

Her lab will assess the protection provided by the Oxford/AstraZeneca, Pfizer/BioNtech and Johnson & Johnson vaccines, while tests on plasma from recovered patients will help to shed light on the risk of reinfection with Omicron. Early reports from South Africa suggest that reinfections are more common with Omicron than the Delta variant, but far more data is needed to be sure.

Moore’s results, which could be available in the next two weeks, are expected to provide some of the first laboratory evidence on whether existing vaccines are sufficient to keep Omicron at bay, or whether manufacturers will need to produce an updated vaccine. But with Omicron carrying so many mutations, making the pseudoviruses is not straightforward. “It will take some time to introduce so many mutations,” Moore said.

What does appearance of Omicron variant mean for the double-vaccinated?

Further work on vaccine protection is under way at the African Health Research Institute in Durban where Prof Alex Sigal, a virologist, is growing batches of live Omicron from people who became infected in the recent surge in Gauteng in South Africa. Once he has enough to work with, the variant will be tested against blood plasma from vaccinated people and those with some natural immunity after a Covid infection.

South African scientists were the first to report the Omicron variant to the World Health Organization on 24 November. At the time, the first known infection was on 9 November, but earlier infections may come to light as countries conduct thorough searches for cases, chiefly among travellers who recently returned from the region.

The work in South Africa is part of an urgent global effort to understand the threat posed by Omicron. Ravi Gupta, professor of clinical microbiology at the University of Cambridge, hopes to join the effort soon, first with pseudoviruses and then with live Omicron. Further experiments, he said, will look at how well synthetic antibody treatments deal with the variant. The therapies are crucial for patients who are not able to mount their own immune response to the virus.

Several vaccine manufacturers have also launched studies into how well the jabs protect against Omicron. AstraZeneca is analysing infections and vaccination status in people in Botswana and Eswatini on the borders of South Africa. Meanwhile, a spokesperson for Pfizer said the company hoped to have initial results from its own antibody studies “in the coming weeks”.

If the variant largely evades vaccines, both Moderna and Pfizer claim they can produce a new, tailor-made vaccine in about 100 days, subject to approval by regulators.


US FDA Approves Merck’s Antiviral Pill

An advisory group for the Food and Drug Administration (FDA) has voted to recommend Merck’s COVID-19 antiviral pill for infected adults at high risk for severe coronavirus illness, hospitalization or death.

The panel narrowly endorsed Merck’s five-day oral treatment in a 13-10 vote on Tuesday.

The advisers recommended the FDA authorize the pill, developed with Ridgeback Biotherapeutics, for adult patients enduring mild to moderate COVID-19 who face a higher risk of serious illness, including due to underlying health conditions.

The drug manufacturer filed for an emergency use authorization last month after its study suggested molnupiravir reduced the risk of hospitalization by 50 percent. But updated data from Friday showed a 30 percent reduction in hospitalizations among more participants.

The close vote came as experts considered concerns about the decreased risk reduction in Merck’s updated data as well as the risks the drug could present for pregnant people.

Several who backed the pill for high-risk infected adults pointed to the ongoing state of emergency amid COVID-19 and the limited treatments for the virus.

“I see this as an incredibly difficult decision,” the committee’s chairperson, Lindsey Baden, said. “There are many, many more questions than answers.”

“But I can see scenarios where there are benefits and therefore having this available for those scenarios makes sense to me,” he added.

Those who voted against the endorsement cited a “modest” effectiveness shown in the data.

Approval of these pills could expand accessibility of at-home COVID-19 treatments, pending FDA authorization and Centers for Disease Control and Prevention approval. The U.S. has already agreed to buy 3.1 million courses of the drug, with the option to purchase more.

Antiviral COVID-19 drugs have been considered a potential game changer in the pandemic since all current drugs require an injection or IV. Other pills are in development, including Paxlovid from Pfizer, which requested FDA authorization earlier this month.

The vote comes after the FDA released its review of Merck’s data on the drug last week that concluded molnupiravir’s effectiveness but raised concerns about its effects on pregnant people.

Merck representatives recommended during the meeting that people who are pregnant or breastfeeding do not take the pills due to potential risks, including possible toxicity and birth defects.

The pharmaceutical company suggested women of childbearing age use contraception while receiving molnupiravir. Merck plans to launch a pregnancy surveillance program to further track the drug’s effects on pregnant people.

Several advisers supported a warning for pregnant people not to take the drug, and some suggested requiring pregnancy testing for patients before they receive the drug.

Merck is also not currently seeking authorization for the pill to be administered to children.

Some experts expressed worries that the drug, which inserts small errors into the virus’s genetic code to prevent replication, could spark the virus to mutate into more dangerous strains, although the FDA considers the issue a “theoretical” concern.

Merck’s pill would not function as a preventative treatment, as it would be administered to already infected individuals to avoid worse outcomes.

The treatment is not designed to replace vaccinations, as COVID-19 vaccines would still be needed to stop infection in the first place. Merck did not study the drug’s effects among vaccinated people.

The advisers’ decision also comes as anxiety has mounted over the World Health Organization’s most recent variant of concern: the omicron strain.

A Merck representative told the FDA in the meeting that the company has not tested molnupiravir against the omicron variant, but they expect the pill to remain effective against the strain.


Covid: UK aims for 500,000 jabs a day in bid to outpace Omicron variant

Ministers to ramp up vaccinations to 3.5m a week as minimum gap for boosters is halved to three months

A mobile NHS ‘vaccination on wheels team’ in Windsor. A senior government source says the government were aiming for 2.4m boosters a week to about 3.5m or 500,000 a day.
A mobile NHS ‘vaccination on wheels team’ in Windsor. A senior government source says the government were aiming for 2.4m boosters a week to about 3.5m or 500,000 a day. Photograph: Maureen McLean/Rex/Shutterstock

Ministers are targeting a return to half a million UK Covid jabs a day as the waiting time for boosters was cut to three months in a bid to outpace the Omicron variant that scientists believe is already spreading in the community.

Confirmed Omicron cases rose to 11 in England and Scotland on Monday, with scientific advisers braced for hundreds more to be detected in the next week or so.

From Tuesday, masks will be mandatory on public transport including airports and stations and in shops – including hair salons and takeaways but not pubs or restaurants – to slow the spread of Omicron, which is feared to more transmissible with the potential to evade vaccines.

The NHS is set to confirm an expansion of the vaccine programme this week after the government’s advisers said all adults should be offered boosters and made the surprise recommendation of a three- rather than six-month wait after a second dose.

Outdoor vaccination site
What changes have been announced for Covid booster jabs in UK?

A senior government source told the Guardian ministers were aiming for a “significant acceleration” from the current 2.4m boosters a week to about 3.5m or 500,000 a day – a return to the huge national effort seen in the early days of the vaccination campaign. “That is the early plan but it won’t happen overnight,” they said.

Currently, boosters are restricted to over-40s more than six months since their last jab. The first new cohort of people to be offered boosters is likely to be those over-40s and the clinically vulnerable who are more than three but less than six months past their second jabs. The next tranches will be under-40s in staggered age groups from oldest to youngest. Children aged 12 to 15 will be offered second doses for the first time, and people who are severely immunosuppressed will get boosters in addition to three primary doses.

The biggest unvaccinated group remains under-12s. Dr June Raine, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA), said this was being “very carefully assessed” and the agency is likely to report before Christmas on the safety of vaccines for children aged 5-11. It would also have to be approved by the Joint Committee on Vaccination and Immunisation (JCVI) before a final decision being taken by government ministers.

As the threat of the Omicron variant prompted the JCVI to ramp up the jabs rollout, Prof Jonathan Van-Tam, the deputy chief medical officer, said people needed to “up their game” in terms of getting boosters.

But he added: “I do not want people to panic at this stage. If vaccine effectiveness is reduced [with Omicron], as seems pretty likely to some extent, the biggest effects are likely to be in preventing infections and hopefully there will be smaller effects on preventing severe disease.”

Prof Wei Shen Lim, chair of the JCVI, said Moderna or Pfizer boosters would push up people’s immune response and cutting the time between doses could help mitigate any drop in vaccine protection before another wave starts.

The planned extension of the booster programme means another 13m under-40s will become eligible for third jabs in the coming weeks. The NHS is currently administering 350,000 daily boosters, or about 2.4m a week, and would have to increase to 500,000 a day to hit 3.5m a week.

An NHS source said there were 2,2oo vaccination centres in operation which means that, on average, every site would have to vaccinate 70 more Britons a day to hit 3.5m boosters a week. Sources said it was easier to expand opening hours than open new centres, raising the prospect of more “round-the-clock” provision.

Boris Johnson published details on Monday of new regulations to make mask wearing compulsory on transport and in shops from 4am on Tuesday. This includes hair salons, taxis, vets, takeaway shops, driving instruction vehicles, banks and post offices, though hospitality settings are exempt.

All travellers into the UK will also have to take a PCR test on the second day after arrival and isolate until they receive a negative test. In addition, all contacts of people suspected to have Covid with the Omicron variant must isolate, even if they are double vaccinated or under 18.

Ahead of a vote on the measures in the House of Commons on Tuesday, Johnson said: “The measures taking effect today are proportionate and responsible, and will buy us time in the face of this new variant … our vaccines and boosters remain our best line of defence.”

The measures will be reviewed in three weeks, but some backbench Tories are already concerned about possible extensions. Mark Harper, one of key MPs behind the Covid Recovery Group, warned measures should not be extended during parliament’s recess just before Christmas. “Trust between the backbenchers and ministers isn’t brilliant at the moment. The government would be wise not to make that worse,” he said.

Sajid Javid, the health secretary, told parliament that if Omicron was no more dangerous than the dominant Delta variant “then we will not keep measures in place a day longer than necessary”.


Biden faces new political threat in omicron

The Hill

The White House on Monday was dealing with the latest and most serious threat yet to President Biden’s pledge to “shut down” the coronavirus: a new variant that experts worry is easily spread and could elude vaccines.

While experts cautioned that much remains unknown about the omicron variant, travel restrictions have quickly been reimposed to limit its spread, and the government on Monday stepped up calls for people to get booster shots to maximize protections.

For Biden, whose faltering poll numbers have left Democrats openly worried they could lose their House and Senate majorities next year, the variant adds to an already difficult political climate fueled by inflation and goods shortages exacerbated by supply chain problems.

Republicans seized on omicron as fuel for their attacks that Biden has failed to contain the pandemic, while Biden appeared before the cameras to reassure the public of his leadership on the central issue of his presidency.

“This variant is a cause for concern, not a cause for panic,” Biden said. “We have the best vaccine in the world, the best medicines, the best scientists, and we’re learning more every single day. And we’ll fight this variant with scientific and knowledgeable actions and speed, not chaos and confusion.”

Those final words served as a reminder to those watching of the Trump administration, which was widely criticized for its handling of the coronavirus.

Through the first six months of Biden’s presidency, his handling of the pandemic was a clear strength after the tumultuous year in which Trump presided over it, a period that culminated with Trump getting a serious case of the disease.

The tide has since turned on Biden, however, with cases and deaths rising over the summer despite vaccines. Republicans have taken to highlighting how there have been more U.S. deaths from COVID-19 this year than the previous year.

“Biden failed to shut down the virus as he promised,” Republican National Committee spokeswoman Emma Vaughn said in a Monday statement.

Those deaths were mostly fueled by an epidemic among the unvaccinated, a minority that has refused to take vaccines despite repeated pushes by Biden. Democrats have also noted that some Republicans have effectively sabotaged a pandemic recovery by casting doubt on vaccines and other restrictions that might lower the spread of the disease. Yet it is unclear whether those Republican politicians — or Biden and Democrats — will be the ones punished by voters in 2022 and beyond.

Health experts agree that the pathway out of the pandemic is through vaccination, but Biden’s sweeping coronavirus vaccine mandate for businesses is being held up in court and faces an uncertain future.

On Monday, a federal court temporarily halted Biden’s mandate for health workers at hospitals that receive federal funding in 10 states that sued to block the administration’s November rule, arguing that the mandate would lead to staff shortages.

Meanwhile, fatigue from the nearly two-year pandemic has set in for many Americans, making Biden’s challenge all the more difficult.

“We’re going to deal with this for a while and I think [Biden] has to tell Americans there is no definitive end,” said Basil Smikle, Democratic strategist and director of Hunter College’s public policy program. “This comes in phases.”

“He needs to be able to say that this is how we weather these fluctuations and give us instructions about how we move forward,” he said.

White House officials blame Biden’s sinking poll numbers on public weariness with the pandemic.

Yet they also argue the country is undeniably in a better position now than when Trump was in charge. A majority of Americans are now vaccinated and there has been real progress in developing treatments.

On the economic front, there has been a drastic decline in unemployment claims and the economy is creating jobs, despite the real problems of the supply chain and inflation.

Part of the challenge for Biden is the expectation game, which might have been worsened by the partial victory lap he took on July 4, just as the more contagious delta variant was beginning to spread in the U.S. Omicron is now another threat to the expectations from voters that Biden will move the country beyond the coronavirus.

“It was kind of short sighted and foolish because it raised expectations when we were nowhere near the end of the pandemic,” said Lawrence Gostin, a public health law professor at Georgetown University. “And what the omicron variant shows us is that we’re a long way out until this becomes simply an endemic disease that we tolerate and manage.”

Gostin said Biden needs to set expectations with a simple message: “America is in for a long road and that the only way that we can protect ourselves is to vaccinate everyone in America and everyone abroad, beginning with America first.”

One former Trump administration official who worked on the pandemic response suggested the Biden administration was caught flat-footed at the outset of the delta variant surge. They argued the aggressive response to omicron could be an overcorrection amid bad poll numbers.

Experts have said it will likely take at least a couple of weeks before more is known about the omicron strain and how effective vaccines are in preventing serious illness. Biden, who has sought to distinguish himself from his predecessor by offering a more aggressive response to the pandemic along with a more cohesive vaccine distribution and embracing the advice of health experts, will visit the National Institutes of Health later this week.

A Washington Post-ABC poll released earlier this month illustrated how the public’s view of Biden’s handling of the pandemic has steadily declined over the past six months.

An April poll found 64 percent of the public approved of Biden’s work on the pandemic, but a poll conducted Nov. 7-10 found just 47 percent gave Biden positive marks on that issue. That decline aligns with a broader dip in his overall approval rating.

The pandemic could become yet another front where the White House has to play defense heading into the midterms as Biden and his team rebuff attacks from Republicans over inflation, immigration, employment and government spending.

“The masks and vaccination polarization is going to deepen if this mutation, this variant, starts to move through our population more significantly,” said Smikle. “It will just renew all of those tensions going into the midterms.”



Coronavirus Cases:





Highlighted in green
= all cases have recovered from the infection
Highlighted in grey
= all cases have had an outcome (there are no active cases)

[back to top ↑]

Latest News

December 1 (GMT)


  • 32,837 new cases and 1,226 new deaths in Russia [source]

- Advertisement -